Earlier this week, San Diego startup Gallant introduced $18 million in funding to deliver the primary FDA-approved ready-to-use stem cell remedy to veterinary medication. If it passes regulatory muster, it may create an entire new strategy to deal with our fur infants.
Support authors and subscribe to content
This is premium stuff. Subscribe to read the entire article.
Login if you have purchased
